See more : Shanxi Blue Flame Holding Company Limited (000968.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Sonnet BioTherapeutics Holdings, Inc. (SONN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sonnet BioTherapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Metallica Minerals Limited (MLMZF) Income Statement Analysis – Financial Results
- G Collado, S.A.B. de C.V. (COLLADO.MX) Income Statement Analysis – Financial Results
- WalkMe Ltd. (WKME) Income Statement Analysis – Financial Results
- Studio City International Holdings Limited (MSC) Income Statement Analysis – Financial Results
- Mahaan Foods Limited (MAHAANF.BO) Income Statement Analysis – Financial Results
Sonnet BioTherapeutics Holdings, Inc. (SONN)
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.63K | 147.81K | 349.94K | 483.63K | 0.00 | 40.61M | 30.73M | 41.43M | 41.70M | 42.40M | 0.00 | 17.50M | 6.88M | 1.46M | 136.30K | 684.68K | 234.06K |
| Cost of Revenue | 0.00 | 11.81M | 93.26K | 16.63M | 58.31K | 7.93M | 29.94M | 39.41M | 38.38M | 14.04M | 0.00 | 0.00 | 2.76M | 360.81K | 11.08K | 684.68K | 234.06K |
| Gross Profit | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | 32.68M | 791.11K | 2.03M | 3.33M | 28.36M | 0.00 | 17.50M | 4.12M | 1.10M | 125.22K | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -7,893.43% | 73.35% | -3,339.55% | 0.00% | 80.47% | 2.57% | 4.89% | 7.98% | 66.89% | 0.00% | 100.00% | 59.87% | 75.35% | 91.87% | 0.00% | 0.00% |
| Research & Development | 5.74M | 11.81M | 21.44M | 16.63M | 9.88M | 2.20M | 154.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 363.88K | 4.55M | 5.80M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.50M | 0.00 | 145.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.13M | 7.13M | 8.58M | 8.94M | 7.53M | 2.51M | 3.86M | 4.55M | 5.95M | 7.42M | 0.00 | 0.00 | 2.62M | 1.25M | 935.11K | 2.24M | 2.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 125.50K | 0.00 | 11.05M | 11.05M | 5.19M | 3.45M | 3.36M | 0.00 | -23.29M | 0.00 | 0.00 | 0.00 | -1.12M | -1.14M |
| Operating Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 3.86M | 4.55M | 5.95M | 10.78M | 0.00 | -23.29M | 2.62M | 1.25M | 935.11K | 1.12M | 1.14M |
| Cost & Expenses | 11.87M | 18.94M | 30.02M | 25.57M | 17.41M | 4.71M | 33.80M | 43.95M | 44.32M | 24.82M | 0.00 | -23.29M | 9.75M | 2.18M | 946.19K | 1.13M | 1.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 15.00 | 20.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.54K | 46.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 20.68K | 162.87K | 381.68K | -2.59M | -2.35M | -3.47M | 0.00 | 0.00 | -474.93K | -180.83K | 140.02K | 33.91K | 20.49K |
| Depreciation & Amortization | 0.00 | 75.75K | 93.26K | 95.16K | 58.31K | 3.54M | 1.82M | 2.28M | 2.34M | 2.36M | 0.00 | 0.00 | 383.45K | 87.62K | 11.08K | 11.48K | 11.20K |
| EBITDA | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | -13.15M | -3.71M | -2.93M | 541.15K | -2.73M | 0.00 | -3.91M | -3.24M | -1.18M | -878.82K | -376.05K | -2.21M |
| EBITDA Ratio | -63,617.91% | -12,663.22% | -8,463.34% | -5,163.13% | 0.00% | -11.59% | -4.08% | -0.57% | -0.67% | -31.68% | 0.00% | -33.13% | -47.06% | -80.75% | -644.76% | -54.92% | -942.91% |
| Operating Income | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | -4.71M | -3.07M | -2.52M | -2.62M | -11.49M | 0.00 | -5.80M | -2.87M | -714.31K | -809.89K | -444.49K | -949.99K |
| Operating Income Ratio | -63,617.91% | -12,714.47% | -8,478.34% | -5,187.36% | 0.00% | -11.59% | -9.99% | -6.08% | -6.28% | -27.10% | 0.00% | -33.13% | -41.69% | -48.80% | -594.19% | -64.92% | -405.88% |
| Total Other Income/Expenses | 4.41M | -40.08K | -52.48K | 103.48K | -27.34K | -162.87K | -7.38M | -5.29M | -1.53M | 3.59M | 0.00 | 508.78K | -505.46K | -379.90K | -220.03K | -369.21K | -1.29M |
| Income Before Tax | -7.44M | -18.83M | -29.72M | -24.98M | -24.27M | -4.87M | -8.07M | -7.81M | -4.15M | -14.32M | 0.00 | -5.96M | -3.38M | -1.09M | -1.03M | -813.70K | -2.24M |
| Income Before Tax Ratio | -39,929.30% | -12,741.58% | -8,493.34% | -5,165.97% | 0.00% | -11.99% | -26.26% | -18.85% | -9.95% | -33.78% | 0.00% | -34.07% | -49.04% | -74.75% | -755.62% | -118.84% | -956.45% |
| Income Tax Expense | 0.00 | 0.00 | 52.48K | 22.03K | 6.80M | 162.87K | -701.22K | -644.43K | 198.46K | -187.57K | 0.00 | 0.00 | 19.21K | 14.61K | 0.00 | 0.00 | 0.00 |
| Net Income | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M | -5.03M | -6.85M | -6.79M | -9.08M | -12.14M | 0.00 | -5.96M | -3.17M | -1.10M | -1.01M | -813.70K | -2.24M |
| Net Income Ratio | -39,929.30% | -12,741.58% | -8,508.34% | -5,170.52% | 0.00% | -12.40% | -22.30% | -16.40% | -21.77% | -28.63% | 0.00% | -34.07% | -46.01% | -75.38% | -742.16% | -118.84% | -956.45% |
| EPS | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| EPS Diluted | -11.35 | -18.14 | -150.79 | -313.76 | -1.02K | -5.78K | -15.59K | -21.55K | -33.50K | -42.60K | 0.00 | -68.28K | -1.25 | -0.47 | -175.20K | -540.70K | -1.57M |
| Weighted Avg Shares Out | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
| Weighted Avg Shares Out (Dil) | 655.24K | 1.04M | 197.46K | 79.70K | 30.59K | 871.48 | 439.58 | 315.31 | 270.92 | 284.91 | 191.00 | 87.31 | 2.54M | 2.37M | 5.77 | 1.50 | 1.42 |
Hot Penny Stocks To Buy on Robinhood? Here's 4 To Watch
Sonnet BioTherapeutics Provides 2021 Business Update
Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations
2 Falling Knives to Catch
Source: https://incomestatements.info
Category: Stock Reports